Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR
详细信息 查看全文
- 作者：Zuoguang Wanga ; wzg70@hotmail.com" class="auth_mail" title="E-mail the corresponding author ; Qiuli Niua ; 1 ; Xiaoyun Pengb ; Mei Lia ; Kuo Liua ; Ya Liua ; Jielin Liua ; Fei Jina ; Xiao Lia ; Yongxiang Weia ; wyhhzq818@sina.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：LVH ; left ventricular hypertrophy ; VSMC ; vascular smooth muscle cell ; EH ; essential hypertension ; Mfn2 ; mitofusin 2 ; SHR ; spontaneously hypertensive rat ; WKY ; Wistar-Kyoto rat ; Δψm ; mitochondrial membrane potential ; ROS ; reactive oxygen species ; BW ; body weight ; HW ; heart weight ; SOD ; superoxide dismutase ; ARB ; angiotensin II Type 1 receptor blocker ; TOD ; target organ damage
- 刊名：International Journal of Cardiology
- 出版年：2016
- 出版时间：1 July 2016
- 年：2016
- 卷：214
- 期：Complete
- 页码：348-357
- 全文大小：1574 K
文摘
- •
Candesartan cilexetil antihypertensive treatment attenuated SHR cardiac remodeling
- •
Candesartan cilexetil antihypertensive treatment improved SHR mitochondrial morphology, structure, and function.
- •
Candesartan cilexetil antihypertensive treatment improved SHR mitofusin2/ras/raf/MEK pathway gene and protein expression.
- •
Mitofusin 2 may be used as a potential marker for cardiac remodeling and a novel therapeutic target.